International Society for Cellular Therapy

International Society for Cellular Therapy
Name	International Society for Cellular Therapy
Abbreviation	ISCT
Formation	1995
Type	Professional association
Purpose	Standards, education, advocacy for cellular therapies
Headquarters	Montreal, Quebec
Region served	International
Membership	Clinicians, researchers, regulators, industry
Leader title	President

International Society for Cellular Therapy is a professional association that brings together clinicians, researchers, industry representatives, and regulators involved in cellular therapy and regenerative medicine. The society fosters development of consensus standards, organizes scientific meetings, and issues position statements that influence practice across fields such as hematology, oncology, transplantation medicine, and regenerative medicine. Members interact with international bodies including World Health Organization, European Medicines Agency, and national agencies to align clinical translation and manufacturing of cell-based products.

History

Founded in 1995 by a coalition of clinicians from transplant centers and basic scientists involved with bone marrow transplantation, the society emerged amid rapid advances in hematopoietic stem cell transplantation and early trials of mesenchymal stem cells. Early leaders included investigators affiliated with institutions such as Fred Hutchinson Cancer Research Center, MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, and University of Pennsylvania. Over subsequent decades the society expanded its remit to interact with regulatory agencies like the United States Food and Drug Administration and the European Medicines Agency, and to engage with professional organizations including the International Society for Stem Cell Research, American Society of Hematology, American Society of Gene & Cell Therapy, and regional groups such as the European Society for Blood and Marrow Transplantation.

Mission and Objectives

The society’s stated objectives include establishing technical and clinical standards for cellular therapies, promoting translational science, and advocating for patient safety and harmonized regulation. It works with stakeholders including physician-scientists, manufacturing organizations, and health authorities to develop guidance relevant to gene therapy, cellular immunotherapy, and tissue engineering. The society advances education through collaboration with academic centers like Stanford University, Harvard Medical School, Oxford University, and consortia such as the International Alliance for Biological Standardization.

Governance and Membership

Governance is typically vested in an elected board of directors and committees drawn from a global membership representing academic centers, clinical networks, and industry partners such as Novartis, Gilead Sciences, Johnson & Johnson, and biotechnology firms. Membership categories span clinician members, scientist members, and corporate members, with regional chapters connecting to networks in North America, Europe, Asia, and Latin America. The society collaborates with accreditation entities like Joint Commission-affiliated programs and university hospital systems including Massachusetts General Hospital and Toronto General Hospital.

Conferences and Workshops

Annual meetings convene researchers, clinicians, and industry delegates alongside satellite workshops on manufacturing and regulatory science. Scientific programming often features sessions in partnership with organizations such as American Society of Clinical Oncology, European Society for Medical Oncology, International Academy of Stem Cell Application, and university consortia from Karolinska Institutet and University College London. Workshops address topics including good manufacturing practice (GMP), quality systems, and clinical trial design, drawing faculty from centers like Mayo Clinic, Cleveland Clinic, and Johns Hopkins Hospital.

Publications and Position Statements

The society issues consensus statements, guidance documents, and white papers that are widely cited by journals and guideline bodies. These publications are disseminated in outlets including Cytotherapy (journal), Blood (journal), The Lancet, Nature Medicine, and Science Translational Medicine. Position statements have covered cell characterization, potency assays, and definitions for cell types such as mesenchymal stromal cells, with cross-references to standards from International Organization for Standardization and regional regulatory guidance from entities like the Medicines and Healthcare products Regulatory Agency.

Standards and Accreditation Programs

To promote reproducibility and safety, the society develops technical standards and contributes to accreditation frameworks for cell processing facilities, harmonizing parameters such as identity, purity, and potency assays. It collaborates with standard-setting organizations including International Organization for Standardization and professional accreditation bodies such as College of American Pathologists while interfacing with national health technology assessment agencies like National Institute for Health and Care Excellence that influence reimbursement and clinical adoption.

Research and Clinical Impact

Through consensus standards, educational programs, and networking, the society has shaped conduct of clinical trials in areas including chimeric antigen receptor T cell therapy, allogeneic stem cell transplantation, and cell-based tissue repair. Its guidance has been cited in pivotal trials at centers like Seattle Cancer Care Alliance, Princess Margaret Cancer Centre, and Dana-Farber Cancer Institute. By engaging with regulators, payers, and research funders such as National Institutes of Health, European Commission, and philanthropic organizations including the Bill & Melinda Gates Foundation, the society has influenced pathways for translation from bench to bedside across international clinical and manufacturing ecosystems.

Category:Medical and health organizations